Figure 2From: Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone Progression-free survival (A) and overall survival (B) by treatment group, among women with advanced breast cancer treated with mitoxantrone or CMFP (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone). Back to article page